Summary

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

In this report, the data of China comes from NICPBP (National Institutes for Food and Drug Control).
ICRWorld's 23-Valent Pneumococcal Polysaccharide Vaccine market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving revenue growth and profitability.
The industry report lists the leading competitors and provides the insights strategic industry analysis of the key factors influencing the market.
The report includes the forecasts, analysis and discuion of important industry trends, market size, market share estimates and profiles of the leading industry players.
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market: Product Segment Analysis
Single Dose Vial
Pre-filled Syringe
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market: Application Segment Analysis
For Children (2-10)
For Person (10-64)
For The old (?65)
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market: Regional Segment Analysis
USA
Europe
Japan
China
India
South East Asia
The players mentioned in our report
MSD
Sanofipasteur
CDIBP